Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP773507.RAvkP3LeXwLf_Cr7YLErZXL19aBovG9FOTTFYH-kCOsIo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP773507.RAvkP3LeXwLf_Cr7YLErZXL19aBovG9FOTTFYH-kCOsIo130_assertion type Assertion NP773507.RAvkP3LeXwLf_Cr7YLErZXL19aBovG9FOTTFYH-kCOsIo130_head.
- NP773507.RAvkP3LeXwLf_Cr7YLErZXL19aBovG9FOTTFYH-kCOsIo130_assertion description "[In early clinical studies, mTOR inhibitors have been well tolerated, resulted in plasma levels able to inhibit mTOR in normal and tumor tissues of patients treated with the drug, and resulted in antitumor responses in patients with different tumor types including lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP773507.RAvkP3LeXwLf_Cr7YLErZXL19aBovG9FOTTFYH-kCOsIo130_provenance.
- NP773507.RAvkP3LeXwLf_Cr7YLErZXL19aBovG9FOTTFYH-kCOsIo130_assertion evidence source_evidence_literature NP773507.RAvkP3LeXwLf_Cr7YLErZXL19aBovG9FOTTFYH-kCOsIo130_provenance.
- NP773507.RAvkP3LeXwLf_Cr7YLErZXL19aBovG9FOTTFYH-kCOsIo130_assertion SIO_000772 16159415 NP773507.RAvkP3LeXwLf_Cr7YLErZXL19aBovG9FOTTFYH-kCOsIo130_provenance.
- NP773507.RAvkP3LeXwLf_Cr7YLErZXL19aBovG9FOTTFYH-kCOsIo130_assertion wasDerivedFrom befree-20140225 NP773507.RAvkP3LeXwLf_Cr7YLErZXL19aBovG9FOTTFYH-kCOsIo130_provenance.
- NP773507.RAvkP3LeXwLf_Cr7YLErZXL19aBovG9FOTTFYH-kCOsIo130_assertion wasGeneratedBy ECO_0000203 NP773507.RAvkP3LeXwLf_Cr7YLErZXL19aBovG9FOTTFYH-kCOsIo130_provenance.